Table 3.
Efficacy of sabizabulin at ≥ 63 mg daily (n = 55).
| Parameter | Result |
|---|---|
|
| |
| Radiographic progresssion-free survival, months (n = 55) | |
| Median (95% CI) | 11.4 (29.63–65.79) |
| ITT population, all patients with measurable disease at baseline (n = 29) | |
| Objective response rate | CR 1/29, PR 5/29, CR+PR = 6/29 (20.7%) |
| PSA (n = 48) a | |
| Any PSA decline - evaluable patients | 14/48 (29%) |
| 50% PSA decline | 4/48 (8%) |
Seven patients did not have baseline PSA levels and could not be evaluable for PSA declines.